CONNECT WITH US
HealthTech

HealthTech

IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV

Medical Xpress logo

Published on

Add as a preferred source on Google
IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic suppression among virologically suppressed adults with HIV, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.

Ricky Hsu, M.D., from the AIDS Healthcare Foundation in Los Angeles, and colleagues examined real-world persistence and virologic outcomes after a switch to CAB+RPV LA and explored reasons for discontinuation. ART-experienced, virologically suppressed adults switching to CAB+RPV LA from Jan. 21, 2021, to Dec. 31, 2025, were observed through Feb. 28, 2026.

Overall, 87% of the 7,995 people who switched to CAB+RPV LA were suppressed at initiation. The researchers found that 77% of the 6,362 complete initiators (first two injections ≤67 days apart) remained in care and on CAB+RPV LA at study end, with a median duration of 18 months on CAB+RPV LA. Ninety-four percent had their last viral load measured at <50 copies/mL during the first uninterrupted CAB+RPV LA use, while 81% maintained all viral loads <50 copies/mL and 1% experienced confirmed virologic failure.

The most common reasons for discontinuation were nonadherence to injection visits, loss to care and desire to switch to oral ARTs (29%, 23% and 15%, respectively), among 182 surveys of provider-confirmed discontinuations.

"By adding real-world data that reflects everyday challenges facing patients in accessing care to the evidence base, these findings further validate randomized clinical trials that show cabotegravir plus rilpivirine as an effective and valuable option for those living with HIV," Hsu said in a statement.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.